Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
Silexion Therapeutics priced a $2.5 million public offering of 3,846,161 ordinary shares or equivalents with accompanying Series E warrants at $0.65 per share. The financing extends a clinical-stage RNAi developer’s runway but puts fresh dilution and a deeply negative earnings profile directly in focus.
STOCK PHOTO · RDNE STOCK PROJECTThe story
Silexion Therapeutics announced pricing for a $2.5 million public offering comprising 3,846,161 ordinary shares or ordinary-share equivalents and Series E warrants to purchase up to 3,846,161 ordinary shares, at a combined price of $0.65 per share or equivalent with accompanying warrants. The company is developing RNA interference therapies for KRAS-driven cancers.
The financing gives Silexion additional capital, but the structure adds a large block of shares and warrants for a clinical-stage company. Finnhub enrichment shows reported revenue of $155,000, up 453.6% year over year, alongside a net margin of -7685.2% and diluted EPS of $89.61, underscoring the gap between early revenue and current profitability.
The setup is therefore dominated by financing mechanics rather than operating traction: the capital may support development, while the offering price and warrant package create an immediate dilution overhang. The key next checks are the final warrant terms, the company’s cash runway and the market’s reaction to the new share supply.
Our read · Tue, Aug 11
The $2.5 million offering and matching warrant coverage move the near-term risk to the downside for SLXN, despite 453.6% year-over-year revenue growth from a very small base.
Why. The financing adds 3,846,161 shares or equivalents and warrants for up to 3,846,161 shares at $0.65, creating a clear supply and dilution overhang. Revenue is only $155,000 despite 453.6% year-over-year growth, while net margin is -7685.2%, leaving the company dependent on external capital.
Both cases
What could change this view: A sharp clinical, partnership or financing announcement that improves confidence in the RNAi pipeline could overwhelm the offering-related supply pressure.
Who reported it · 1
Keep reading
Latest on the Wire
Hyperscale Data warns of $74.8 million gap for Michigan AI projectAlibaba aided China military-linked lab with AI computing technologyMeta pauses plan to give Zuckerberg new shares without losing controlFed releases October meeting minutes three weeks after policy decisionAnthropic Said to Guide IPO Pricing Above Market RangeContinue on the Wire →Latest on the Wire
Xi gives Trump a rare hug at Shenzhen airport as US-China tone softensLagarde says she will leave ECB early to counter election misinformationRansomware group The Gentlemen reportedly lists Nvidia for a leak'Renter Nation' Juices Starts; Building Permits Plunge To COVID Lows As Homebuilder Confidence CrashesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseNvidia CFO Colette Kress to serve as interim CEO after Jensen HuangAbout this report
Reported by GlobeNewswire, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →